About Dragonfly Sciences
Dragonfly Sciences aims to be a leader and an innovator in developing and selling biosimilar products.
Dragonfly Sciences focuses on the development of high value, complex biosimilar molecules –
monoclonal antibodies and soluble receptors. Dragonfly will pursue opportunities
to launch biosimilar products via a dual strategy for the EU and US markets and
for select rest-of-world markets.
Founded in 2005, Dragonfly’s
management team brings extensive pharmaceutical and biotechnology industry
experience in the discovery and development of antibody therapeutics. With
headquarters in the United States, Dragonfly operates research and development
labs in Zhangjiang Hi-tech Park in
Dragonfly is dedicated to
reproducing originator drug molecules using the highest quality technical and
analytical techniques in order to meet Western regulatory standards. Core
competencies include cell line generation, assay development, state-of-the-art
bioanalytics, and process development. The Company will add clinical
development, sales and marketing capabilities as candidates progress in
development.
